Back to top
more

Strongbridge Biopharma PLC (SBBP)

(Delayed Data from NSDQ)

$3.21 USD

3.21
609,525

-0.20 (-5.87%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Strongbridge Biopharma (SBBP) Reports Q3 Loss, Tops Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 11.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 40.00% and 27.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Strongbridge Biopharma (SBBP) Report Negative Q2 Earnings? What You Should Know

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strongbridge Biopharma (SBBP) Reports Q1 Loss, Tops Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 5.00% and 11.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Strongbridge Biopharma (SBBP) Report Negative Earnings Next Week? What You Should Know

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strongbridge Biopharma (SBBP) Reports Q4 Loss, Tops Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 7.41% and 12.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Strongbridge Biopharma (SBBP) Reports Q3 Loss, Tops Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 7.41% and 12.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Strongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Strongbridge Biopharma (SBBP) Report Negative Q3 Earnings? What You Should Know

Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 7.69% and 26.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Strongbridge Biopharma (SBBP) Reports Q1 Loss, Lags Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 26.47% and -7.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Aeterna (AEZS) This Earnings Season?

Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.

Strongbridge Biopharma (SBBP) Reports Q3 Loss, Misses Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of -2.17% and -2.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Strongbridge Biopharma (SBBP) Reports Q2 Loss, Lags Revenue Estimates

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 25.00% and -5.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

Strongbridge Biopharma (SBBP) Rises: Stock Moves 17% Higher

Strongbridge Biopharma plc (SBBP) shares rose almost 17% in the last trading session.

Strongbridge (SBBP) Shows Strength: Stock Moves Up 10.1%

Strongbridge Biopharma plc (SBBP) moved big last session, as the company saw its shares rise over 10% on the day.

Can The Uptrend Continue for Strongbridge Biopharma (SBBP)?

Investors certainly have to be happy with Strongbridge Biopharma plc (SBBP) and its short term performance